inca33890
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 24, 2023 (NCT05836324)
Timeline
Indications
Studied for
Mechanism of action
- TGF-beta receptor type IIINHIBITOR
TGFBR2 inhibitor
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284849 | Phase 3 | Feb 16, 2026 | Incyte |
| NCT05836324 | Phase 1 | Jul 24, 2023 | Incyte |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1